Humanized single domain antibodies neutralize SARS-CoV-2 by targeting the spike receptor binding domain.

ABSTRACT: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spreads worldwide and leads to an unprecedented medical burden and lives lost. Neutralizing antibodies provide efficient blockade for viral infection and are a promising category of biological therapies. Here, using SARS-CoV-2 spike receptor-binding domain (RBD) as a bait, we generate a panel of humanized single domain antibodies (sdAbs) from a synthetic library. These sdAbs reveal binding kinetics with the equilibrium dissociation constant (K_D) of 0.99-35.5 nM. The monomeric sdAbs show half maximal neutralization concentration (EC₅₀) of 0.0009-0.07 µg/mL and 0.13-0.51 µg/mL against SARS-CoV-2 pseudotypes, and authentic SARS-CoV-2, respectively. Competitive ligand-binding experiments suggest that the sdAbs e

SUBMITTER: Chi X 

PROVIDER: S-EPMC7483421 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature